company background image
RXST

RxSightNasdaqGM:RXST Stock Report

Last Price

US$10.95

Market Cap

US$299.5m

7D

-5.8%

1Y

n/a

Updated

19 Jan, 2022

Data

Company Financials +
RXST fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

RXST Stock Overview

RxSight, Inc., a medical technology company, develops light adjustable lens (LAL) to improve uncorrected visual acuity that can be adjusted enhance uncorrected visual acuity after cataract surgery.

RxSight Competitors

HOYA

TSE:7741

JP¥5.9t

Alcon

SWX:ALC

CHF35.0b

Carl Zeiss Meditec

XTRA:AFX

€12.7b

Bausch Health Companies

NYSE:BHC

US$9.6b

Price History & Performance

Summary of all time highs, changes and price drops for RxSight
Historical stock prices
Current Share PriceUS$10.95
52 Week HighUS$19.67
52 Week LowUS$8.80
Beta0
1 Month Change6.73%
3 Month Change-7.05%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-31.56%

Recent News & Updates

Aug 26

RxSight: First And Only Customizable Intraocular Lens

RxSight has commercialized the first and only FDA approved customizable intraocular lens. The Company closed an IPO recently with gross proceeds of $132 million. Analysts are very bullish with the company’s prospects.

Shareholder Returns

RXSTUS Medical EquipmentUS Market
7D-5.8%-5.0%-3.5%
1Yn/a0.8%10.2%

Return vs Industry: Insufficient data to determine how RXST performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how RXST performed against the US Market.

Price Volatility

Is RXST's price volatile compared to industry and market?
RXST volatility
RXST Average Weekly Movement12.3%
Medical Equipment Industry Average Movement8.1%
Market Average Movement6.6%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.4%

Stable Share Price: RXST is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: Insufficient data to determine RXST's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1997171Ron Kurtzhttps://www.rxsight.com

RxSight, Inc., a medical technology company, develops light adjustable lens (LAL) to improve uncorrected visual acuity that can be adjusted enhance uncorrected visual acuity after cataract surgery. It also offers RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017.

RxSight Fundamentals Summary

How do RxSight's earnings and revenue compare to its market cap?
RXST fundamental statistics
Market CapUS$299.53m
Earnings (TTM)-US$14.70m
Revenue (TTM)US$19.08m

15.7x

P/S Ratio

-20.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RXST income statement (TTM)
RevenueUS$19.08m
Cost of RevenueUS$16.05m
Gross ProfitUS$3.03m
ExpensesUS$17.72m
Earnings-US$14.70m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.54
Gross Margin15.87%
Net Profit Margin-77.02%
Debt/Equity Ratio26.3%

How did RXST perform over the long term?

See historical performance and comparison

Valuation

Is RxSight undervalued compared to its fair value and its price relative to the market?

1.99x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate RXST's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate RXST's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: RXST is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: RXST is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RXST's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RXST is good value based on its PB Ratio (2x) compared to the US Medical Equipment industry average (3.5x).


Future Growth

How is RxSight forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

18.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RXST is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RXST is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RXST is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RXST's revenue (37% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: RXST's revenue (37% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: RXST is forecast to be unprofitable in 3 years.


Past Performance

How has RxSight performed over the past 5 years?

-261.7%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: RXST is currently unprofitable.

Growing Profit Margin: RXST is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if RXST's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare RXST's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RXST is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (51.2%).


Return on Equity

High ROE: RXST has a negative Return on Equity (-4.41%), as it is currently unprofitable.


Financial Health

How is RxSight's financial position?


Financial Position Analysis

Short Term Liabilities: RXST's short term assets ($186.3M) exceed its short term liabilities ($9.2M).

Long Term Liabilities: RXST's short term assets ($186.3M) exceed its long term liabilities ($43.7M).


Debt to Equity History and Analysis

Debt Level: RXST has more cash than its total debt.

Reducing Debt: Insufficient data to determine if RXST's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: RXST's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if RXST's interest payments on its debt are well covered by EBIT.


Balance Sheet


Dividend

What is RxSight current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RXST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RXST's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RXST's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RXST's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RXST's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.9yrs

Average management tenure


CEO

Ron Kurtz (58 yo)

6yrs

Tenure

US$740,683

Compensation

Dr. Ronald M. Kurtz, also known as Ron, M.D., serves as President and Chief Executive Officer at RxSight, Inc. (formerly Calhoun Vision) since January 2016 and also serves as its Director since February 20...


CEO Compensation Analysis

Compensation vs Market: Ron's total compensation ($USD740.68K) is below average for companies of similar size in the US market ($USD1.10M).

Compensation vs Earnings: Insufficient data to compare Ron's compensation with company performance.


Leadership Team

Experienced Management: RXST's management team is considered experienced (4.9 years average tenure).


Board Members

Experienced Board: RXST's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: RXST insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: RXST only recently listed within the past 12 months.


Top Shareholders

Company Information

RxSight, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: RxSight, Inc.
  • Ticker: RXST
  • Exchange: NasdaqGM
  • Founded: 1997
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Implied Market Cap: US$299.525m
  • Shares outstanding: 27.35m
  • Website: https://www.rxsight.com

Number of Employees


Location

  • RxSight, Inc.
  • 100 Columbia
  • Suite 120
  • Aliso Viejo
  • California
  • 92656
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/19 00:06
End of Day Share Price2022/01/18 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.